Virus News and Research

Latest Virus News and Research

Nuvilex realizes important role for Cell-in-a-Box technology

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions through acquisition of SG Austria assets, realizes the important role for Cell-in-a-Box technology and aims to bring to light its use in the production of therapeutic antibodies for clinically important diseases.

4 Apr 2012

MedImmune's quadrivalent flu vaccine may protect children

An intranasal vaccine that includes four weakened strains of influenza could do a better job in protecting children from the flu than current vaccines, Saint Louis University research shows.

4 Apr 2012

Scientists discover new anti-HCV antibodies

A team led by scientists at The Scripps Research Institute has found antibodies that can prevent infection from widely differing strains of hepatitis C virus (HCV) in cell culture and animal models.

4 Apr 2012

SFU receives NIH grant to develop effective HIV/AIDS vaccine

Jamie Scott, a Simon Fraser University professor and Canada Research Chair in molecular immunity, and three international collaborators are getting a hefty financial boost in their efforts to develop an effective HIV/AIDS vaccine.

4 Apr 2012

Young girls face increased risk of side effects after Gardasil vaccination

Younger girls are more likely than adult women to report side effects after receiving Gardasil, the human papillomavirus vaccine.

4 Apr 2012

Combination of carboplatin, paclitaxel and RT3D shows promise against head and neck cancer

A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published in Clinical Cancer Research.

4 Apr 2012

Funding shortfalls could hinder implementation of treatment as prevention strategies, Al Jazeera reports

Al Jazeera examines the administration of combination antiretroviral therapy (ART) worldwide, focusing on treatment as prevention (TasP), but says current funding levels are insufficient to implement the strategy.

3 Apr 2012

Positive outcome from AiCuris’ Letermovir phase 2b trial on HCMV infections

AiCuris announced today that data on the positive outcome of Letermovir (AIC246) tested in a phase 2b trial in transplant patients will be disclosed at several international meetings on behalf of the AIC246 study team.

3 Apr 2012

Merck announces data from ZOSTAVAX Phase III study on shingles

Merck, known as MSD outside the United States and Canada, announced today that data from the pivotal Phase III study with ZOSTAVAX(Zoster Vaccine Live) in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases.

3 Apr 2012

Controversial study on lethal bird flu virus strain to be published

The controversial study on lethal flu virus strain is likely to be published in full. Last December the National Science Advisory Board for Biosecurity - NSABB recommended the two papers not be published in full by the journals - Nature and Science. The panel was concerned that details of the studies, which induced mutations in the H5N1 avian flu virus that made it transmissible among mammals by air rather than by close physical contact, could be used for bioterrorism. Critics of the recommendation raised fears that important science was being censored.

2 Apr 2012

Study sheds light on cellular mechanisms involved in flu resistance

Scientists from the University of Utah School of Medicine have discovered that a mouse protein called IFITM3 contributes to the body's defense against some types of viral infections by binding to an enzyme responsible for regulating the pH of a cell's waste disposal system.

2 Apr 2012

New diagnostic test for Trichomonas vaginalis

Medical Diagnostic Laboratories, L.L.C. is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

2 Apr 2012

NanoViricides reports positive pre-IND meeting with USFDA for FluCide

NanoViricides, Inc. announced today that its previously announced pre-IND Meeting was held with the USFDA on March 29th, 2012, as scheduled. This pre-IND meeting focused on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.

2 Apr 2012

Inovio awarded U.S. DOD grant to advance non-invasive surface electroporation delivery device

Inovio Pharmaceuticals, Inc. announced today it has received a U.S. Department of Defense Small Business Innovation Research Grant to advance the development of a low-cost, non-invasive surface electroporation (EP) delivery device and test its utility in combination with Inovio's novel synthetic DNA vaccines against viruses with bioterrorism potential, including hanta, puumala, arenavirus and pandemic influenza.

2 Apr 2012

RT3D may boost effects of two standard chemotherapy drugs in head and neck cancer patients

2 Apr 2012

New guidelines offer guidance on how and when to switch between RA drug classes

A trend toward more aggressive treatment in patients just starting to develop rheumatoid arthritis is among the most important changes in treatment guidelines for the disease, according to updated American College of Rheumatology recommendations published today in the journal Arthritis Care & Research. The trend may proceed from emerging opinions that joint damage caused by RA is irreversible, and that early, intensive therapy better preserves physical function, quality of life and capacity to work.

2 Apr 2012

India's success against polio is promising step in defeating disease worldwide

"That India is free of wild polio today is a testament to the commitment of the Indian government," which "invested more than $1 billion over the last decade and collaborated with community leaders, health workers, businesses, and parents," as well as governments, non-governmental organizations, and multilateral agencies, to fight the disease, Health and Human Services (HHS) Secretary Kathleen Sebelius writes in a Foreign Affairs opinion piece.

31 Mar 2012

U.S. releases policy requiring dual-use biological research reviews amid bird flu debate

"The U.S. government on Thursday released a new policy that will require federal agencies to systematically review the potential risks associated with federally funded studies involving 15 'high consequence' pathogens and toxins, including the H5N1 avian influenza virus," Science Insider reports.

31 Mar 2012

Dengue infection makes mosquito's blood feeding more efficient

Mosquitoes infected with dengue virus experience an array of changes in the activity of genes and associated functions of their salivary glands, and these changes may lead to increased virus transmission, according to a recent study led by George Dimopoulos, Ph.D., of the Malaria Research Institute and Bloomberg School of Public Health at Johns Hopkins University.

31 Mar 2012

Abbott receives CE Marking for PLEX-ID instrument and assays

Abbott announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput PLEX-ID instrument, along with three assays for use on the system: PLEX-ID Viral IC Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu.

31 Mar 2012